DEXCOM INC DXCM
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
7/9
Piotroski F — financial health
4.98
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $4.7B | $836.3M | $2.8B | $1.1B | $2.7B |
| 2024 | $4.0B | $576.2M | $2.4B | $630.7M | $2.1B |
| 2023 | $3.6B | $541.5M | $2.3B | $511.9M | $2.1B |
| 2022 | $2.9B | $341.2M | $1.9B | $304.7M | $2.1B |
| 2021 | $2.4B | $216.9M | $1.7B | $53.3M | $2.0B |
| 2020 | $1.9B | $549.7M | $1.3B | $276.6M | $1.6B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| FOLETTA MARK G | director | 2026-06-15 | Sell | 3,801 | $74.10 |
| FOLETTA MARK G | director | 2026-06-15 | Sell | 199 | $74.82 |
| Brown Michael Jon | EVP Chief Legal Compliance Off | 2026-06-15 | Sell | 1,700 | $75.55 |
| Coleman Jon | EVP, Chief Commercial Officer | 2026-06-04 | Sell | 4,911 | $74.13 |
| Coleman Jon | EVP, Chief Commercial Officer | 2026-06-03 | Sell | 4,912 | $73.00 |
| Heller Bridgette P | director | 2026-05-28 | Grant | 5,575 | — |
| Osterloh Albert Frederick IV | director | 2026-05-28 | Grant | 1,630 | — |
| Driscoll Rimma | director | 2026-05-28 | Grant | 5,605 | — |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.98 (safe)
- Working capital / assets 0.298
- Retained earnings / assets 0.384
- EBIT / assets 0.144
- Equity / liabilities 0.764
Source: SEC EDGAR filings · CIK 0001093557 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.